Skip to Main Content

Paper Details

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
J Exp Med
114
2021
AR IFNAR1 or IFNAR2 deficiency, COVID-19 pneumonia, IFN-2, IFNAR1, IFNAR2, IFNAR2 deficiency, YFV, Yellow fever, Yellow fever virus, auto, patient, patients, type I IFNs, vaccine-associated disease, viral illness, yellow fever
Author NameAffiliation
Hans-Heinrich HoffmannThe Rockefeller University
Bali PulendranEmory University School of Medicine
Bali PulendranInstitute for Immunity, Stanford University
Bali PulendranEmory University School of Medicine
Bali PulendranInstitute for Immunity, Stanford University
Rafi AhmedEmory University School of Medicine
Charles M RiceThe Rockefeller University
  • 1 - 7

Datasets

Release 1.2